Veppanu
Coverage of Veppanu in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more
The article discusses upcoming public visibility of drug prices under Trump's most-favored-nation deals, highlighting three new drugs (Baxfendy, Awiqli, and Veppanu). CVS Health is reintroducing Eli Lilly's obesity drug Zepbound to formularies and removing coverage restrictions on Lilly's new weight loss pill Foundayo.
- STAT+: Trump’s drug-pricing deals set to be tested by new product launches
President Trump's most-favored-nation drug pricing deals with 17 drugmakers will be tested by three new prescription drugs set to launch soon. The drugs, Baxfendy (hypertension), Awiqli (insulin), and Veppanu (cancer), will offer the first public insight into the practical impacts of these secretive pricing agreements.
- STAT+: Hims’ sales miss as telehealth competition grows
Rigel Pharma will market the newly approved breast cancer drug Veppanu, while Roche received European clearance for a new blood test to detect early Alzheimer’s disease. BridgeBio submitted an application to the FDA seeking approval of its drug encaleret to treat patients with autosomal dominant hypocalcemia type 1. Bristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs.